Neurocrine Biosciences
$143.18Change from previous close: +1.76%Absolute change: +$2.47
At a glance
- Revenue growth
- +21.45%
- 2025 vs 2024
- Net income growth
- +40.23%
- 2025 vs 2024
- Net margin
- 16.7%
- 2024: 14.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 2,861 | 2,355 | 1,887 | 1,489 | — |
| Cost of revenue | 52.1 | 34.0 | 39.7 | 23.2 | — |
| Gross profit | 2,808 | 2,321 | 1,847 | 1,466 | — |
| Selling, general and administrative | 1,156 | 1,007 | 888 | 753 | — |
| Research and development | 1,016 | 731 | 565 | 464 | — |
| Operating income | 637 | 583 | 395 | 249 | — |
| EBIT | 637 | 613 | 395 | 249 | — |
| EBITDA | 667 | 640 | 416 | 265 | — |
| Interest expense | — | 127 | 4.6 | 7.1 | 25.8 |
| Pre-tax income | 705 | 486 | 332 | 214 | — |
| Income tax | 227 | 145 | 82.4 | 59.4 | — |
| Net income | 479 | 341 | 250 | 155 | — |
| Net income to common shareholders | 479 | 341 | 250 | 155 | — |
| Basic EPS | 4.81 | 3.40 | 2.56 | 1.61 | — |
| Diluted EPS | 4.67 | 3.29 | 2.47 | 1.56 | — |
| Average shares (basic) | 99.5 | 100 | 97.7 | 95.8 | — |
| Average shares (diluted) | 103 | 104 | 101 | 98.9 | — |